CXCR4 is a
chemokine receptor implicated in the homing of
cancer cells to target metastatic organs, which overexpress its
ligand, stromal cell-derived factor (SDF)-1. To determine the efficacy of targeting CXCR4 on primary
tumor growth and
metastasis, we used a
peptide inhibitor of CXCR4,
CTCE-9908, that was administered in a clinically relevant approach using a transgenic
breast cancer mouse model. We first performed a dosing experiment of
CTCE-9908 in the PyMT mouse model, testing 25, 50 and 100 mg/kg versus the scrambled
peptide in groups of 8-16 mice. We then combined
CTCE-9908 with
docetaxel or DC101 (an anti-VEGFR2
monoclonal antibody). We found that increasing doses of
CTCE-9908 alone slowed the rate of
tumor growth, with a 45% inhibition of primary
tumor growth at 3.5 weeks of treatment with 50 mg/kg of
CTCE-9908 (p = 0.005). Expression levels of
VEGF were also found to be reduced by 42% with
CTCE-9908 (p = 0.01). In combination with
docetaxel,
CTCE-9908 administration decreased
tumor volume by 38% (p = 0.02), an effect that was greater than that observed with
docetaxel alone. In combination with DC101,
CTCE-9908 also demonstrated an enhanced effect compared to DC101 alone, with a 37% decrease in primary
tumor volume (p = 0.01) and a 75% reduction in distant
metastasis (p = 0.009). In combination with
docetaxel or an anti-angiogenic agent, the anti-
tumor and anti-metastatic effects of
CTCE-9908 were markedly enhanced, suggesting potentially new effective combinatorial therapeutic strategies in the treatment of
breast cancer, which include targeting the SDF-1/CXCR4
ligand/receptor pair.